Trial of Myocet in Metastatic Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by Sopherion Therapeutics.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Sopherion Therapeutics
ClinicalTrials.gov Identifier:
NCT00294996
First received: February 17, 2006
Last updated: March 30, 2009
Last verified: March 2009
  Purpose

The purpose of the study is to examine the safety and effectiveness of the drug combination of Myocet, paclitaxel and trastuzumab compared to paclitaxel and trastuzumab without Myocet, as first line treatment for patients with metastatic HER2+ breast cancer.


Condition Intervention Phase
Breast Cancer
Drug: Myocet
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by Sopherion Therapeutics:

Primary Outcome Measures:
  • Progression-Free Survival

Secondary Outcome Measures:
  • Overall Survival
  • Safety

Enrollment: 363
Study Start Date: January 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Metastatic Her2+ Breast cancer by FISH analysis
  • No prior chemotherapy for metastatic disease
  • Measurable disease
  • normal left ventricular ejection fraction

Exclusion Criteria:

  • prior doxorubicin treatment exceeding 300 mg/m2 or epirubicin exceeding 600 mg/m2
  • relapse within 12 months of completion of adjuvant trastuzumab, taxane or anthracycline therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00294996

  Show 105 Study Locations
Sponsors and Collaborators
Sopherion Therapeutics
Investigators
Principal Investigator: Jose Baselga, M.D. Vall d'Hebron Hospital, Barcelona, Spain
  More Information

No publications provided by Sopherion Therapeutics

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00294996     History of Changes
Other Study ID Numbers: STM01-102
Study First Received: February 17, 2006
Last Updated: March 30, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Sopherion Therapeutics:
Metastatic Her2+ Breast cancer
Myocet
liposomal doxorubicin
trastuzumab

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Trastuzumab
Doxorubicin
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 28, 2014